Vaishnavi Salokhe

Prof. Vaishnavi Salokhe

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
NSNilesh Kumar Sharma
Nilesh Kumar Sharma
ABAnjali Bahot
Anjali Bahot
GSGopinath Sekar
Gopinath Sekar
MBMahima Bansode
Mahima Bansode
KKKratika Khunteta
Kratika Khunteta
Birandra K. K SinhaBirandra K. K Sinha
Birandra K. K Sinha
In recent years, the emergence of cancer drug resistance has been one of the crucial tumor hallmarks that are supported by the level of genetic heterogeneity and complexities at cellular levels. Oxidative stress, immune evasion, metabolic reprogramming, overexpression of ABC transporters, and stemness are among the several key contributing molecular and cellular response mechanisms. Topo-active drugs, e.g., doxorubicin and topotecan, are clinically active and are utilized extensively against a wide variety of human tumors and often result in the development of resistance and failure to therapy. Thus, there is an urgent need for an incremental and comprehensive understanding of mechanisms of cancer drug resistance specifically in the context of topo-active drugs. This review delves into the intricate mechanistic aspects of these intracellular and extracellular topo-active drug resistance mechanisms and explores the use of potential combinatorial approaches by utilizing various topo-active drugs and inhibitors of pathways involved in drug resistance. We believe that this review will help guide basic scientists, pre-clinicians, clinicians, and policymakers toward holistic and interdisciplinary strategies that transcend resistance, renewing optimism in the ongoing battle against cancer.

1 March 1993 in Journal of Terramechanics
Verified
Journal Article
Closed access
VSVaishnavi Salokhe
Vaishnavi Salokhe
NNNguyen The Ninh
Nguyen The Ninh